Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 5/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13512970 | 0.84 | HTT (0.51) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL2722714 | 0.84 | SYK (0.54) | CTSSCTSLCTSBSYKCTSK | |
| SCHEMBL2722985 | 0.83 | CTSL (0.54) | CTSSCTSLCTSBSYKCTSK | |
| SCHEMBL4549859 | 0.81 | SYK (0.51) | CTSSCTSLCTSBSYKCTSK | |
| SCHEMBL3707986 | 0.81 | SYK (0.46) | CTSSCTSLCTSBSYKSMN1; SMN2 | |
| SCHEMBL6897899 | 0.79 | HTT (0.54) | CTSSCTSLCTSBSMN1; SMN2NPC1 | |
| SCHEMBL28032465 | 0.79 | CTSS (0.54) | CTSSCTSLCTSBCTSKNPC1 | |
| SCHEMBL7352450 | 0.79 | CTSS (0.60) | CTSSCTSLCTSBSYKCTSK | |
| SCHEMBL14737847 | 0.79 | SYK (0.56) | CTSSCTSLCTSBSYKSMN1; SMN2 | |
| SCHEMBL25568624 | 0.78 | SYK (0.50) | CTSSCTSLCTSBSYKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030489-B2 | Ornithine derivative | ASTELLAS PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100216803-A1 | ORNITHINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2141147-A1 | ORNITHINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | PTGER4, OXER1, ODC1 | CTSS 4049/4885CTSL 3240/4885CTSB 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.